Cargando…
α(V)β(6) Integrin: An Intriguing Target for COVID‐19 and Related Diseases
The outbreak of SARS‐CoV‐2 has been an extraordinary event that constituted a global health emergency. As the novel coronavirus is continuing to spread over the world, the need for therapeutic agents to control this pandemic is increasing. α(V)β(6) Integrin may be an intriguing target not only for t...
Autor principal: | Bugatti, Kelly |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426704/ https://www.ncbi.nlm.nih.gov/pubmed/34132013 http://dx.doi.org/10.1002/cbic.202100209 |
Ejemplares similares
-
Nintedanib-Containing Dual Conjugates Targeting α(V)β(6) Integrin and Tyrosine Kinase Receptors
as Potential Antifibrotic Agents
por: Bugatti, Kelly, et al.
Publicado: (2022) -
Therapeutic Radiopharmaceuticals Targeting Integrin
αvβ6
por: Färber, Stefanie Felicitas, et al.
Publicado: (2018) -
Therapeutic Targeting of Integrin αvβ6 in Breast Cancer
por: Moore, Kate M., et al.
Publicado: (2014) -
Nintedanib-αVβ6 Integrin Ligand Conjugates Reduce TGFβ-Induced EMT in Human Non-Small Cell Lung Cancer
por: Andreucci, Elena, et al.
Publicado: (2023) -
Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation
por: Brown, Wells S, et al.
Publicado: (2014)